milatuzumab
mAbexperimental
Milatuzumab is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia. — Wikipedia
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00421525)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Graft vs Host Disease · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Lupus Erythematosus, Cutaneous · Phase 1/Phase 2
- Lupus Erythematosus, Discoid · Phase 1/Phase 2
- Lupus Erythematosus, Systemic · Phase 1/Phase 2
- Lupus Nephritis · Phase 1/Phase 2
- Lupus Vasculitis, Central Nervous System · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1
- Plasmacytoma · Phase 1/Phase 2
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMilatuzumab ↗
- ChEMBLCHEMBL1743040 ↗
Also known as
- hll1
- hll1
- hll1-dox
- immu-115
- immu-115
- milatuzumab
- milatuzumab
- milatuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01845740 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Department of Defense, Immunomedics |
| NCT01663766 | Phase 1 | Dec 1, 2013 | Immunomedics, Ohio State University |
| NCT01585688 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2012 | Immunomedics |
| NCT01101594 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2010 | Immunomedics |
| NCT00989586 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2009 | Immunomedics, Ohio State University |
| NCT00868478 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2009 | Hebrew University, Immunomedics |
| NCT00603668 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2008 | Immunomedics |
| NCT00504972 | Phase 1 | Jun 1, 2007 | Cornell University, Immunomedics |
| NCT00421525 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2007 | Immunomedics |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunomedics | For profit | 9 | 6 | 2 | 2007 |
| Ohio State University | Academic/Hospital | 2 | 1 | 2 | 2009 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Department of Defense | Government | 1 | 0 | 1 | 2015 |
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 2009 |
5 organizations
Page 1 / 1